Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Semergen
|
September 13, 2018
[Available resources for the management of chronic obstructive pulmonary disease exacerbations in Spain]
J J Soler-Cataluña, A Fernández Villar, P L Piñera Salmerón, et al.
Alimentary Pharmacology & Therapeutics
|
January 16, 2007
Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study)
V Garrigues, F Mearin, X Badía, et al.
Scandinavian Journal of Gastroenterology
|
November 1, 2001
Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population
F Mearin, X Badía, A Balboa, et al.
Alimentary Pharmacology & Therapeutics
|
March 25, 2006
Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients
F Mearin, X Badía, A Balboa, et al.
Autoimmunity Reviews
|
January 15, 2014
Patterns of systemic lupus erythematosus expression in Europe
R Cervera, A Doria, Z Amoura, et al.
Actas Urologicas Espanolas
|
September 17, 1999
[The development and preliminary validation of the IU-4 questionnaire for the clinical classification of urinary incontinence]
X Badia Llach, D Castro Díaz, L Perales Cabañas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 15, 2016
Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients
A Rosell, N Rodríguez, E Monsó, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2006
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
M Martín, A Lluch, M A Seguí, et al.
Alimentary Pharmacology & Therapeutics
|
April 4, 2007
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate
M Diago, A Olveira, R Solá, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Semergen
|
September 13, 2018
[Available resources for the management of chronic obstructive pulmonary disease exacerbations in Spain]
J J Soler-Cataluña, A Fernández Villar, P L Piñera Salmerón, et al.
Alimentary Pharmacology & Therapeutics
|
January 16, 2007
Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study)
V Garrigues, F Mearin, X Badía, et al.
Scandinavian Journal of Gastroenterology
|
November 1, 2001
Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population
F Mearin, X Badía, A Balboa, et al.
Alimentary Pharmacology & Therapeutics
|
March 25, 2006
Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients
F Mearin, X Badía, A Balboa, et al.
Autoimmunity Reviews
|
January 15, 2014
Patterns of systemic lupus erythematosus expression in Europe
R Cervera, A Doria, Z Amoura, et al.
Actas Urologicas Espanolas
|
September 17, 1999
[The development and preliminary validation of the IU-4 questionnaire for the clinical classification of urinary incontinence]
X Badia Llach, D Castro Díaz, L Perales Cabañas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 15, 2016
Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients
A Rosell, N Rodríguez, E Monsó, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2006
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
M Martín, A Lluch, M A Seguí, et al.
Alimentary Pharmacology & Therapeutics
|
April 4, 2007
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate
M Diago, A Olveira, R Solá, et al.
Page
of 4